• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 7:32:15 AM ET
    $OXFD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OXFD alert in real time by email
    SC 13G/A 1 polar-oxfd123120a4.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A 

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*



    Oxford Immunotec Global PLC

    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.006705

    (Title of Class of Securities)

     

    G6855A103

    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 2 of 7 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    England
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,568,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,568,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,568,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.89%
    12
    TYPE OF REPORTING PERSON
     
    HC

     

     


     

    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 3 of 7 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    England
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,568,385
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,568,385
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,568,385
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.89%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 4 of 7 Pages

     

    Item 1.(a) Name of Issuer

    Oxford Immunotec Global PLC

    (b) Address of Issuer’s Principal Executive Offices

    94C Innovation Drive, Milton Park

    Abingdon OX14 4RZ, United Kingdom

    Item 2.(a) Name of Person Filing

    Polar Capital Holdings Plc

    Polar Capital LLP

    (b) Address of Principal Business Office, or, if none, Residence

    16 Palace Street

    London SW1E 5JD

    (c) Citizenship

    England

     (d) Title of Class of Securities

    Ordinary Shares, nominal value £0.006705

     (e) CUSIP No.:

    G6855A103

     
     

     

    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 5 of 7 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 6 of 7 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 2,568,385

    (b) Percent of class: 9.89%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 2,568,385

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 2,568,385

     

    Polar Capital LLP

    (a) Amount beneficially owned: 2,568,385

    (b) Percent of class: 9.89%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 2,568,385

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 2,568,385

     

    * Based on 25,961,817 Ordinary Shares, which is the total number of shares outstanding as reported in the Issuer's Form 10-Q for the quarterly period ended September 30, 2020 on October 26, 2020.

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Information for each Subsidiary is incorporated on the respective cover pages.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  G6855A103
     SCHEDULE 13G/A
    Page 7 of 7 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021

     

    POLAR CAPITAL HOLDINGS PLC
           
      By: John Mansell
        Name:  John Mansell
        Title:  Executive Director

     

      POLAR CAPITAL LLP
           
      By: Nicholas Farren
        Name:  Nicholas Farren
        Title:  Head of Operations

     

     

     

     

     

     

     

    Get the next $OXFD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OXFD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OXFD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:45 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:19 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:36:57 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

      OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. T-SPOT®.COVID, a Test from Oxford Immunotec Global PLC for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infe

      3/4/21 2:26:00 PM ET
      $OXFD
      $PKI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit. Based on the Company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is

      2/8/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit, for research use only, has been updated using the Company’s growing expertise of the T cell response to SARS-CoV-2 infection. The previous T-SPOT Discovery SARS-CoV-2 kit configuration included five antigen wells, each containing a mix of peptides representing target epitopes derived from the virus, with areas of high homology to endemic coronaviruses removed. Using the Company’s growing results database, it has

      2/4/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Financials

    Live finance-specific insights

    See more
    • Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection. Based on the company’s T-SPOT technology, the only globally approved E

      12/2/20 9:00:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oxford Immunotec Global PLC

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      5/7/21 5:05:21 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      3/8/21 5:05:38 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)

      2/17/21 3:14:15 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    SEC Filings

    See more
    • SEC Form 15-12B filed by Oxford Immunotec Global PLC

      15-12B - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/18/21 4:35:17 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:38:00 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:35:16 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Leadership Updates

    Live Leadership Updates

    See more
    • PerkinElmer to Acquire Oxford Immunotec Global PLC

      WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina

      1/7/21 7:00:00 AM ET
      $PKI
      $OXFD
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care